000136855 001__ 136855
000136855 005__ 20240229105103.0
000136855 0247_ $$2doi$$a10.1088/1361-6560/aad43f
000136855 0247_ $$2pmid$$apmid:30020079
000136855 0247_ $$2ISSN$$a0031-9155
000136855 0247_ $$2ISSN$$a1361-6560
000136855 0247_ $$2altmetric$$aaltmetric:46407257
000136855 037__ $$aDKFZ-2018-01293
000136855 041__ $$aeng
000136855 082__ $$a570
000136855 1001_ $$0P:(DE-He78)ec2298bfd32b6affb60b6154f5481c31$$aDolde, Kai$$b0$$eFirst author$$udkfz
000136855 245__ $$a4D dose calculation for pencil beam scanning proton therapy of pancreatic cancer using repeated 4DMRI datasets.
000136855 260__ $$aBristol$$bIOP Publ.$$c2018
000136855 3367_ $$2DRIVER$$aarticle
000136855 3367_ $$2DataCite$$aOutput Types/Journal article
000136855 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1543836986_20970
000136855 3367_ $$2BibTeX$$aARTICLE
000136855 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136855 3367_ $$00$$2EndNote$$aJournal Article
000136855 520__ $$a4D magnetic resonance imaging (4DMRI) has a high potential for pancreatic cancer treatments using proton therapy, by providing time-resolved volumetric images with a high soft-tissue contrast without exposing the patient to any additional imaging dose. In this study, we aim to show the feasibility of 4D treatment planning for pencil beam scanning (PBS) proton therapy of pancreatic cancer, based on five repeated 4DMRI datasets and 4D dose calculations (4DDC) for one pancreatic cancer patient. To investigate the dosimetric impacts of organ motion, deformation vector fields were extracted from 4DMRI, which were then used to warp a static CT of the patient, so as to generate synthetic 4DCT (4DCT-MRI). CTV motion amplitudes  <15 mm were observed for this patient. The results from 4DDC show pronounced interplay effects in the CTV with dose homogeneity d5/d95 and dose coverage v95 being 1.14 and 91%, respectively, after a single fraction of the treatment. An averaging effect was further observed when increasing the number of fractions. Motion effects can become less dominant and dose homogeneity d5/d95  =  1.03 and dose coverage v95  =  [Formula: see text] within the CTV can be achieved after 28 fractions. The observed inter-fractional organ and tumor motion variations underline the importance of 4D imaging before and during PBS proton therapy.
000136855 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000136855 588__ $$aDataset connected to CrossRef, PubMed,
000136855 7001_ $$aNaumann, Patrick$$b1
000136855 7001_ $$0P:(DE-He78)172522ec1028ab781d9dfd17eaca4427$$aDávid, Christian$$b2$$udkfz
000136855 7001_ $$0P:(DE-He78)77bc493068847c689d894d2eda891c0c$$aGnirs, Regula$$b3$$udkfz
000136855 7001_ $$0P:(DE-He78)f288a8f92f092ddb41d52b1aeb915323$$aKachelrieß, Marc$$b4$$udkfz
000136855 7001_ $$aLomax, Antony John$$b5
000136855 7001_ $$aSaito, Nami$$b6
000136855 7001_ $$aWeber, Damien Charles$$b7
000136855 7001_ $$0P:(DE-He78)435853c50cec6666e13c237685053577$$aPfaffenberger, Asja$$b8$$udkfz
000136855 7001_ $$aZhang, Ye$$b9
000136855 773__ $$0PERI:(DE-600)1473501-5$$a10.1088/1361-6560/aad43f$$gVol. 63, no. 16, p. 165005 -$$n16$$p165005$$tPhysics in medicine and biology$$v63$$x1361-6560$$y2018
000136855 909CO $$ooai:inrepo02.dkfz.de:136855$$pVDB
000136855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ec2298bfd32b6affb60b6154f5481c31$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)172522ec1028ab781d9dfd17eaca4427$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77bc493068847c689d894d2eda891c0c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f288a8f92f092ddb41d52b1aeb915323$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000136855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)435853c50cec6666e13c237685053577$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000136855 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000136855 9141_ $$y2018
000136855 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136855 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium
000136855 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHYS MED BIOL : 2015
000136855 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136855 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136855 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136855 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136855 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136855 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136855 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136855 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136855 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136855 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136855 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136855 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lMedizinische Physik in der Strahlentherapie$$x0
000136855 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lMedizinische Physik in der Radiologie$$x1
000136855 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x2
000136855 9201_ $$0I:(DE-He78)E025-20160331$$kE025$$lRöntgenbildgebung und Computertomographie$$x3
000136855 980__ $$ajournal
000136855 980__ $$aVDB
000136855 980__ $$aI:(DE-He78)E040-20160331
000136855 980__ $$aI:(DE-He78)E020-20160331
000136855 980__ $$aI:(DE-He78)E010-20160331
000136855 980__ $$aI:(DE-He78)E025-20160331
000136855 980__ $$aUNRESTRICTED